A rapid approach would therefore be to investigate whether patients subjected to AT1R antagonist treatment due to hypertension, diabetic kidney disease or other indications have a better disease outcome or a lower frequency of hospitalization than the general population. This evidence concerns the gene AGTR1 and hypertensive disorder.